In Section A, contributors will receive different doses and schedules of oral ABBV-744 tablet to detect Protected dosing routine. Further individuals will likely be enrolled within the identified monotherapy dosign regimen. In Section B, members will acquire oral ruxolitinib and ABBV-744 will probably be given as "include-on" therapy. In Section https://hayleyc444teo6.bligblogging.com/profile